Benitec Biopharma (FRA:BJ93) Cyclically Adjusted Book per Share: €8.34 (As of Mar. 2026)


FRA:BJ93 Benitec Biopharma Inc FRA:BJ93
34 GF Score
Price €3.06
View Full Analysis

What is Benitec Biopharma Cyclically Adjusted Book per Share?

Benitec Biopharma FRA:BJ93 34 Cyclically Adjusted Book per Share is €8.34 as of Mar. 2026. GuruFocus rates FRA:BJ93 with a GF Score™ of 34/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Benitec Biopharma's adjusted book value per share for the three months ended in Mar. 2026 was €4.616. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €8.34 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Benitec Biopharma's average Cyclically Adjusted Book Growth Rate was -13.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-13), Benitec Biopharma's current stock price is €3.06. Benitec Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €8.34. Benitec Biopharma's Cyclically Adjusted PB Ratio of today is 0.37.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Benitec Biopharma was 0.46. The lowest was 0.00. And the median was 0.00.


Benitec Biopharma  (FRA:BJ93) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Benitec Biopharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=3.06/8.34
=0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Benitec Biopharma was 0.46. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Benitec Biopharma Cyclically Adjusted Book per Share Related Terms


Benitec Biopharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Benitec Biopharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Benitec Biopharma Cyclically Adjusted Book per Share Chart

Benitec Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 46.48 8.36

Benitec Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.87 8.36 6.84 6.79 8.34

FRA:BJ93 vs IPSC, FBRX, AUTL: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Benitec Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benitec Biopharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's Cyclically Adjusted PB Ratio falls into.


FRA:BJ93
34GF Score
Benitec Biopharma Inc FRA:BJ93
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Benitec Biopharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Benitec Biopharma's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.616/330.2130*330.2130
=4.616

Current CPI (Mar. 2026) = 330.2130.

Benitec Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201606 25.656 241.018 35.151
201609 27.484 241.428 37.591
201612 21.609 241.432 29.555
201703 25.079 243.801 33.968
201706 21.503 244.955 28.987
201709 18.069 246.819 24.174
201712 15.355 246.524 20.568
201803 12.010 249.554 15.892
201806 13.753 251.989 18.022
201809 0.000 252.439 0.000
201812 20.309 251.233 26.694
201903 0.000 254.202 0.000
201906 17.137 256.143 22.093
201909 0.000 256.759 0.000
201912 0.000 256.974 0.000
202003 0.000 258.115 0.000
202006 139.862 257.797 179.150
202009 101.046 260.280 128.195
202012 45.026 260.474 57.081
202103 32.442 264.877 40.444
202106 34.528 271.696 41.965
202109 27.347 274.310 32.920
202112 19.938 278.802 23.615
202203 14.195 287.504 16.304
202206 5.667 296.311 6.315
202209 9.723 296.808 10.817
202212 5.158 296.797 5.739
202303 2.674 301.836 2.925
202306 0.113 305.109 0.122
202309 8.207 307.789 8.805
202312 5.473 306.746 5.892
202403 3.883 312.332 4.105
202406 4.352 314.175 4.574
202409 3.232 315.301 3.385
202412 3.093 315.605 3.236
202503 3.533 319.799 3.648
202506 3.214 322.561 3.290
202509 3.038 324.800 3.089
202512 4.671 324.054 4.760
202603 4.616 330.213 4.616

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €8.34 mean?
Benitec Biopharma (FRA:BJ93) has a Cyclically Adjusted Book per Share of €8.34 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Benitec Biopharma and its competitors.
Is Benitec Biopharma's Cyclically Adjusted Book per Share too high?
Benitec Biopharma's current Cyclically Adjusted Book per Share is €8.34. Overall, Benitec Biopharma has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Benitec Biopharma's Cyclically Adjusted Book per Share compare to IPSC and FBRX?
Benitec Biopharma's Cyclically Adjusted Book per Share of €8.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Benitec Biopharma and its competitors. Benitec Biopharma's current Cyclically Adjusted Book per Share is €8.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Benitec Biopharma stock overvalued right now?
Benitec Biopharma (FRA:BJ93) has a current Cyclically Adjusted Book per Share of €8.34. The current Cyclically Adjusted Book per Share is €8.34. Benitec Biopharma's overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Benitec Biopharma (FRA:BJ93), the current Cyclically Adjusted Book per Share is €8.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Benitec Biopharma Business Description

Other Exchanges BNTC:USA
Address 3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
34GF Score

Get the complete analysis for FRA:BJ93

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.06
Price